Type I Interferon Signaling is Required for Oncostatin-M Driven Inflammatory Responses in Mouse Lung

J Interferon Cytokine Res. 2022 Nov;42(11):568-579. doi: 10.1089/jir.2022.0136. Epub 2022 Nov 8.

Abstract

Type I interferons (IFNs) consist of a group of structurally similar cytokines that play an integral role in regulating the immune response to combat lung infections. In certain models type I IFNs have also been associated with suppression of Th2-skewed immune and inflammatory responses. Transient pulmonary overexpression of the gp130 cytokine Oncostatin M (OSM) by Adenovirus vector (AdOSM) induces a robust Th2-skewed cytokine/inflammatory profile in C57Bl/6 murine lungs. In this study we assessed type I IFN function in OSM-mediated inflammation in vivo using Ifnar1-/- C57Bl/6 mice and Ifnar1-deficient cells in vitro. Ifnar1-/- mice showed a significant reduction in AdOSM-induced histopathology (epithelial hyperplasia, alveolar septal wall thickening, cellular infiltration), and levels of IL-6 and chemokine protein (CXCL-1/KC and CCL24/eotaxin-2) in lungs compared with wild-type. Ifnar1-/- murine fibroblasts and human type I IFN receptor (Ifnar)-knockdown fibroblasts were also less responsive to OSM in STAT3 activation and cytokine production compared with Ifnar-sufficient cells in vitro. Exogenous type I IFN induced IL-6 responses in mouse and human fibroblasts and in combination with OSM further stimulated IL-6 production, suggesting a concerted action of type I IFNs and OSM. Taken together, these results demonstrate that cross-talk between IFNAR and OSM signaling enhances cell responses and modulates OSM-driven responses in lung inflammation.

Keywords: Oncostatin M; chemokines; lung inflammation; type I interferons.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Humans
  • Interferon Type I* / metabolism
  • Interleukin-6 / metabolism
  • Lung / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Oncostatin M / metabolism
  • Pneumonia* / pathology

Substances

  • Oncostatin M
  • Interleukin-6
  • Interferon Type I

Grants and funding